• OPEN AN ACCOUNT
Indian Indices
Sensex
78,154.25 -388.19
( -0.49%)
Global Indices
Nasdaq
53,996.18 -61.75
(-0.11%)
Dow Jones
7,774.29 -4.35
(-0.06%)
Hang Seng
66,870.65 1,263.94
(1.93%)
Nikkei 225
10,869.98 -31.11
(-0.29%)
Forex
USD-INR
95.15 -0.05
(-0.05%)
EUR-INR
109.97 0.14
(0.13%)
GBP-INR
128.34 0.21
(0.16%)
JPY-INR
0.60 0.00
(0.09%)

EQUITY - MARKET SCREENER

Anuh Pharma Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs
BSE Code
ISIN Demat
Book Value()
506260
INE489G01022
35.1435185
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
ANUHPHR
17.59
777.64
EPS(TTM)
Face Value()
Div & Yield %
4.41
5
1.93
 

USFDA inspects Cipla subsidiary's manufacturing unit in New York
Jul 18,2026

Cipla announced that an inspection was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of InvaGen Pharmaceuticals Inc. (wholly owned subsidiary of the company) located in Central Islip, Long Island, New York, USA, from 13 July 2026 to 17 July 2026 (EDT).

The inspection was a routine current Good Manufacturing Practices (cGMP) Inspection. On conclusion of the inspection, the company has received 1 (one) inspectional observation in Form 483.